- GERN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $18.5 million.
- GERN traded 1.2 million shares today in the pre-market hours as of 8:48 AM, representing 19.6% of its average daily volume.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in GERN with the Ticky from Trade-Ideas. See the FREE profile for GERN NOW at Trade-Ideas More details on GERN: Geron Corporation, a clinical stage biopharmaceutical company, develops a telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California. Currently there are 2 analysts that rate Geron a buy, no analysts rate it a sell, and 2 rate it a hold. The average volume for Geron has been 2.6 million shares per day over the past 30 days. Geron has a market cap of $377.3 million and is part of the health care sector and drugs industry. The stock has a beta of 2.89 and a short float of 20.3% with 4.67 days to cover. Shares are down 50% year-to-date as of the close of trading on Wednesday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.